Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009...

Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter
2009 Form 10-Q Filing

WAYNE, Pa., Aug. 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq:
ENCO), a full service multinational clinical research organization (CRO)
conducting studies in over 30 countries for many of the world's leading
pharmaceutical and biotechnology companies, today announced that on August 21,
2009, it received a letter from Nasdaq stating that since it had not, as of
the date of the letter, filed its 10-Q for the quarterly period ended June 30,
2009, it was then no longer in compliance with the rules for continued listing
according to Listing Rule 5250(c)(1).

Encorium filed its Form 10-Q for the quarterly period ended June 30, 2009 on
August 21, 2009. As a result, the Company received notice on August 26, 2009
from Nasdaq that it is currently in compliance with Listing Rule 5250(c)(1).

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing
in the design and management of complex clinical trials and Patient Registries
for the pharmaceutical, biotechnology and medical device industries. The
Company's mission is to provide its clients with high quality, full-service
support for their biopharmaceutical and medical device development programs.
Encorium offers therapeutic expertise, experienced team management and
advanced technologies. The Company has drug and biologics development as well
as clinical trial experience across a wide variety of therapeutic areas such
as infectious diseases, cardiovascular, vaccines, oncology, diabetes
endocrinology/metabolism, gene therapy, immunology, neurology,
gastroenterology, dermatology, hepatology, women's health and respiratory
medicine. Encorium believes that its expertise in the design of complex
clinical trials, its therapeutic experience and commitment to excellence, and
its application of innovative technologies, offer its clients a means to more
quickly and cost effectively move products through the clinical development
process.

This press release contains forward-looking statements identified by words
such as "estimate," "project," "expect," "intend," "believe," "anticipate" and
similar expressions. Those statements involve risks and uncertainties, and
actual results could differ materially from those discussed. Factors that
could cause or contribute to such differences include, but are not limited to:
(i) the risk that we may not have sufficient funds to operate our business;
(ii)our success in attracting new business and retaining existing clients and
projects; (iii) the size, duration and timing of clinical trials we are
currently managing may change unexpectedly; (iv) the termination, delay or
cancellation of clinical trials we are currently managing could cause revenues
and cash-on-hand to decline unexpectedly; (v) the timing difference between
our receipt of contract milestone or scheduled payments and our incurring
costs to manage these trials; (vi) outsourcing trends in the pharmaceutical,
biotechnology and medical device industries; (vii) the ability to maintain
profit margins in a competitive marketplace; (viii) our ability to attract and
retain qualified personnel; (ix) the sensitivity of our business to general
economic conditions; (x) other economic, competitive, governmental and
technological factors affecting our operations, markets, products, services
and prices; (xi) announced awards received from existing and potential
customers are not definitive until fully negotiated contracts are executed by
the parties; (xii) our backlog may not be indicative of future results and may
not generate the revenues expected; and (xiii) uncertainties regarding the
availability of additional capital and continued listing of our common stock
on Nasdaq. You should not place undue reliance on any forward-looking
statement. We undertake no obligation to publicly release the result of any
revision of these forward-looking statements to reflect events or
circumstances after the date they are made or to reflect the occurrence of
unanticipated events. Please refer to the section entitled "Risk Factors" in
the Company Annual Report on Form 10-K for the year ended December 31, 2008
and the Company's Quarterly Report on Form 10-Q for the period ended June 30,
2009 for a more complete discussion of factors which could cause our actual
results and financial position to change.

SOURCE Encorium Group, Inc.

Philip L. Calamia, Chief Financial Officer, Encorium Group, Inc.,
+1-610-975-9533